Farxiga patent expiration

What the date means

Farxiga's US exclusivity date is based on generics launched. US generics have already launched, so the loss of exclusivity is under way. It is a small-molecule drug, so copies are generics. Generic launches usually take most of the US volume within months.

Medicare price negotiation

Farxiga was selected for the Medicare Drug Price Negotiation Program. Its negotiated Medicare price takes effect in 2026, 68% below its list price. That is the same year US generics can launch. The discount is measured against list price, before the rebates drugmakers already pay, and applies to Medicare only, so the revenue impact is smaller than the headline number.

What changed for Farxiga

1. 7 April 2026US copies launched
   FDA approved the first US generics of Farxiga

   Several generic dapagliflozin makers were approved at once, ending US exclusivity. FDA

2. August 2024Medicare price
   First Medicare prices set, including Eliquis, Farxiga, Entresto, Enbrel and Stelara

   From 2026: Farxiga 68%, Enbrel 67%, Stelara 66%, Eliquis 56% and Entresto 53% below list price. CMS

Sources

1. AZ FY2025
2. FDA
3. CMS: negotiated prices for 2026